Patients with NSCLC with HER2 exon20ins have not been found to derive a meaningful benefit from lapatinib, a dual EGFR/HER2 inhibitor, as a single agent or in combination with pemetrexed74,75. Here, ERBB2 is linked to non-small cell lung carcinoma.